SCHEMBL25201212

SCHEMBL25201212

CCOc1cc(/C=C/C(=O)c2ccc(Cl)cc2Cl)ccc1O

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCL12 P48061 7/20 0.77
AR P10275 2/20 0.62
TOP2A P11388 1/20 0.62
CXCR4 P61073 1/20 0.54
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
ALDH1A1 P00352 1/20 0.51
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
MEN1 O00255 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
KMT2A Q03164 1/20 0.51
RELA Q04206 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25191078 0.89 CXCL12 (0.60) CXCL12ARTOP2APDE4APDE4B
SCHEMBL25202024 0.87 CXCL12 (0.76) CXCL12ARTOP2APDE4APDE4B
SCHEMBL25199657 0.87 CXCL12 (1.00) CXCL12ARCXCR4MEN1NFKB1
SCHEMBL30837239 0.84 CXCL12 (0.75) CXCL12TOP2ACXCR4PDE4APDE4B
SCHEMBL25196661 0.84 CXCL12 (0.75) CXCL12TOP2ACXCR4PDE4APDE4B
SCHEMBL31233162 0.81 CXCL12 (0.72) CXCL12ARMAOAMAOBMEN1
SCHEMBL4972214 0.81 CXCL12 (0.72) CXCL12ARMAOAMAOBMEN1
SCHEMBL4972217 0.81 CXCL12 (0.72) CXCL12ARMAOAMAOBMEN1
SCHEMBL25199754 0.80 TOP2A (0.63) CXCL12TOP2APDE4APDE4BPDE4C
SCHEMBL25194569 0.80 CXCL12 (0.82) CXCL12ARCXCR4ALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CXCL12 399/4885AR 2737/4885TOP2A 4354/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CXCL12 287/4885AR 3445/4885TOP2A 4555/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CXCL12 287/4885AR 3445/4885TOP2A 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.